Lilly’s Pegilodecakin Fails Pancreatic Cancer Test

Asset came from $1.6bn Armo buy

 
• By Kevin Grogan

The company's immunotherapy failed to improve survival of pancreatic patients compared to chemotherapy. Lilly will be hoping pegilodecakin has more success in NSCLC.

Forest_Tree
Sequoia falls but Lilly hopes Cypress studies fare better • Source: Shutterstock

More from Clinical Trials

More from R&D